ClinicalTrials.Veeva

Find clinical trials for Triple Negative Breast Cancer in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Seattle, WA, USA:

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received a...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Trilaciclib

Phase 2

G1 Therapeutics

Auburn, Washington, United States and 21 other locations

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Seattle, Washington, United States and 49 other locations

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Placebo
Drug: Atezolizumab

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Auburn, Washington, United States and 216 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Renton, Washington, United States and 110 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Niraparib
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Everett, Washington, United States and 226 other locations

This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is bei...

Begins enrollment in 1 month
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: INBRX-106

Phase 2

Providence Health & Services
Providence Health & Services

Seattle, Washington, United States and 3 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Tobemstomig

Phase 2

Roche
Roche

Seattle, Washington, United States and 55 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Paclitaxel
Drug: Gemcitabine

Phase 3

Gilead Sciences
Gilead Sciences

Seattle, Washington, United States and 506 other locations

This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO)...

Active, not recruiting
Triple Negative Breast Cancer
Biological: Pembrolizumab
Device: Immunopulse

Phase 2

OncoSec Medical

Seattle, Washington, United States and 13 other locations

CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-sma...

Enrolling
Relapsed Cancer
TNBC - Triple-Negative Breast Cancer
Biological: LYL797

Phase 1

Lyell Immunopharma

Seattle, Washington, United States and 17 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems